文献速递肝肾功能剂量调整抗栓抗凝管理

阿哌沙班与华法林在严重肾功能不全患者中的安全性与有效性比较

Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment.
PubMed 文献 · Pharmacotherapy · 2017-03-10

本研究为回顾性匹配队列研究,纳入146例严重肾功能不全患者,比较阿哌沙班与华法林的安全性和有效性。结果显示两组大出血和复合出血发生率无显著差异,卒中发生率相似,均无复发性静脉血栓栓塞事件。阿哌沙班可能是严重肾功能不全患者中华法林的合理替代选择。

要点

  • 严重肾功能不全患者中阿哌沙班大出血发生率9.6%,华法林17.8%,差异无统计学意义。
  • 复合出血发生率阿哌沙班21.9%,华法林27.4%,差异无统计学意义。
  • 两组卒中发生率均为7.5%,研究期间均无复发性静脉血栓栓塞事件。

核心结论

  • 阿哌沙班似乎是严重肾功能不全患者中华法林的合理替代选择。

研究设计与样本

  • 回顾性匹配队列研究,在社区医院进行,共纳入146例成人患者,阿哌沙班组73例,华法林组73例。
  • 纳入标准为住院期间使用阿哌沙班或华法林至少一剂,且肌酐清除率<25 ml/minute或血清肌酐>2.5 mg/dl,或接受腹膜透析或血液透析。
  • 华法林组中入院时国际标准化比值达治疗范围的患者,按肾功能和抗凝指征以1:1比例按时间顺序与阿哌沙班组匹配。

主要发现

  • 主要结局大出血发生率阿哌沙班组9.6% vs 华法林组17.8%,p=0.149,差异无统计学意义。
  • 复合出血(大出血、临床相关非大出血和轻微出血)发生率阿哌沙班组21.9% vs 华法林组27.4%,p=0.442,差异无统计学意义。
  • 卒中发生率两组均为7.5%,研究期间两组均无复发性静脉血栓栓塞事件。

临床怎么用

  • 对于严重肾功能不全患者,阿哌沙班可作为华法林的合理替代选择,但需注意该结论基于回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: The U.S. Food and Drug Administration approval of the use of apixaban in patients with a creatinine clearance (CrCl) of < 15 ml/minute or in those receiving dialysis is based only on pharmacokinetic data as clinical trials of apixaban excluded patients with a CrCl of < 25 ml/minute or a serum creatinine concentration (SCr) of > 2.5 mg/dl. Thus, the objective of this study was to evaluate the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. DESIGN: Retrospective, matched-cohort study. SETTING: Community hospital. PATIENTS: A total of 146 adults who received at least one dose of apixaban (73 patients) or warfarin (73 patients) while hospitalized between January 30, 2014, and December 31, 2015, and had a CrCl of < 25 ml/minute or SCr of > 2.5 mg/dl, or who received peritoneal dialysis or hemodialysis, were included. Patients who were taking warfarin and had a therapeutic international normalized ratio on admission were matched consecutively in a 1:1 fashion in chronologic order to patients taking apixaban based on renal function and indication for anticoagulation. MEASUREMENTS AND MAIN RESULTS: The primary outcome was major bleeding. Secondary outcomes included the composite of bleeding (major bleeding, clinically relevant nonmajor bleeding, and minor bleeding) in addition to documented ischemic stroke or recurrent venous thromboembolism. A nonsignificant difference in the occurrence of major bleeding and composite bleeding was observed between patients who received apixaban compared with those who received warfarin (9.6% vs 17.8%, p=0.149, and 21.9% vs 27.4%, p=0.442, respectively). The occurrence of stroke was similar between the groups (7.5% in each group), and no recurrent venous thromboembolism events were noted in either group during the study period. CONCLUSION: Apixaban appears to be a reasonable alternative to warfarin in patients with severe renal impairment.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Stanton BE, Barasch NS, Tellor KB, et al. Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment. Pharmacotherapy. 2017. PMID: 28117916. doi:10.1002/phar.1905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。